How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

Rimando, et al., describe how advances in therapy and improved strategies for inducing remission have led to new GVHD risk factors and high-risk groups in those receiving haploidentical transplants, unrelated donors, older recipient age, prior checkpoint inhibitor and autologous HCT exposure, and patients with benign hematologic disorders. They review the broadening use of PTCy and discuss promising agents on the horizon like abatacept and JAK inhibitors. They illustrate their approach in three high risk case studies.